Aurobindo Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aurobindo Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹117Over the last 3 years, every ₹100 of reported profit came with ₹117 of operating cash.
Higher than 53% of Healthcare companies in India.
Self-Funding Ratio
1.3×Over the last 3 years its own operating cash covered its investment spending (capex) 1.3 times.
Lower than 54% of Healthcare companies in India.
Cash Locked Ratio
₹37For every ₹100 of sales, ₹37 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹33 tied up three years earlier.
More money tied up than 72% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹18Sales grew 36% in 3 years; of every extra ₹100 of sales, ₹18 became extra profit.
Higher than 51% of Healthcare companies in India.
Asset Productivity Ratio
+36% / +47%In 3 years sales changed by +36% while total assets changed by +47%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.8×Debt due within a year is covered 0.8 times by its yearly operating cash.
Lower than 59% of Healthcare companies in India.
Cash Cushion Ratio
+3%Cash, after subtracting all debt, equals 3% of its market value (net cash).
Higher than 73% of Healthcare companies in India.
Tangible Assets Ratio
91%Of every ₹100 the company owns, ₹91 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 67% of Healthcare companies in India.
Tangible Net Worth Ratio
86%Of every ₹100 of net worth, ₹86 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 67% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Aurobindo Pharma Limited owes ₹0.35 for every ₹1 it owns. Net profit rose 1% in the year to Mar 2026, and grew 22% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
24.6Investors pay ₹24.6 for every ₹1 of Aurobindo Pharma Limited's yearly profit, lower than 74% of Healthcare companies in India.
P/B ratio
2.39The share price is 2.39 times Aurobindo Pharma Limited's book value per share, lower than 78% of Healthcare companies in India.
Market cap
₹90,432 CrThe total market value of all of Aurobindo Pharma Limited's shares at today's price (share price × number of shares), larger than 94% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹37,891 CrWhat Aurobindo Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹658.54Net worth divided by the number of shares. The share price of ₹1,572 is 2.4 times this, which is the P/B above.
Return on equity (ROE)
9.8%Aurobindo Pharma Limited earned 9.8% on its shareholders' money over the last year, lower than 68% of Healthcare companies in India.
Owes vs Owns
0.35×Aurobindo Pharma Limited owes ₹0.35 for every ₹1 it owns (low), lower than 56% of Healthcare companies in India.
Dividend yield
NoneAurobindo Pharma Limited does not currently pay a dividend.
Revenue growth
+6%Revenue rose 6% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Profit growth
+1%Net profit rose 1% in the year to Mar 2026, and grew 22% a year on average over 3 years.
Profit margin
10.5%Aurobindo Pharma Limited keeps ₹10 of every ₹100 of revenue as net profit.
Cash quality
1.6×Cash from Aurobindo Pharma Limited's business was 1.6× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
14.7×Aurobindo Pharma Limited's operating profit covered its interest costs 14.7 times in the year to Mar 2026.
Cash vs debt
Net cashAurobindo Pharma Limited held ₹2,507 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Aurobindo Pharma Limited's P/E ratio?
Investors pay ₹24.6 for every ₹1 of Aurobindo Pharma Limited's yearly profit, lower than 74% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Aurobindo Pharma Limited: ₹90,432 Cr ÷ ₹37,891 Cr (31 Mar 2026) = 2.4.
What is Aurobindo Pharma Limited's return on equity?
Aurobindo Pharma Limited earned 9.8% on its shareholders' money over the last year, lower than 68% of Healthcare companies in India.
How much does Aurobindo Pharma Limited owe compared with what it owns?
Aurobindo Pharma Limited owes ₹0.35 for every ₹1 it owns (low), lower than 56% of Healthcare companies in India.
Does Aurobindo Pharma Limited pay a dividend?
No. Aurobindo Pharma Limited does not currently pay a dividend.
Is Aurobindo Pharma Limited's revenue growing?
Revenue rose 6% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.